Home Healthcare Dermatology Drugs Market
dermatology drugs market

Dermatology Drugs Market [(By Therapeutic Area (Atopic Dermatitis, Psoriasis, Acne, Rosacea), By Marketed Therapies (Biologics, Oral Drugs, Topical Drugs), By Approved Treatments (etanercept (Enbrel), infliximab (Remicade), adalimumab (Humira), ustekinumab (Stelara), secukinumab (Cosentyx), ixekizumab (Taltz), golimumab (Simponi), brodalumab (Siliq), and guselkamab (Tremfya), and By Region]: Market Size & Forecast, 2017 – 2022

  • Published Date: Feb 2018
  • Pages: 75
  • Format: PDF
  • Report ID: PM1106
  • Base Year: 2016
  • Historical Data: 2015-2016

Report Content

The Marketed Therapies undertaken in forecast from 2016-2022 are:

  • etanercept; Enbrel
  • infliximab; Remicade
  • adalimumab; Humira
  • ustekinumab; Stelara
  • secukinumab; Cosentyx
  • ixekizumab; Taltz
  • golimumab; Simponi
  • brodalumab; Siliq
  • guselkamab; Tremfya
  • Topical Drugs
  • Oral Antibiotics

The Major Indications in Dermatology Drugs Market Therapy area:

  • Atopic Dermatitis
  • Psoriasis
  • Acne
  • Rosacea

 Leading Companies investigated in the Report are

  • Allergan Plc
  • Valeant Pharmaceuticals
  • Dermira Inc
  • Aclaris Therapeutics, Inc
  • AnaptysBio, Inc
  • Revance Therapeutics
  • Foamix Pharmaceuticals
  • Novan, Inc
  • Sienna Biopharmaceuticals
  • Pfizer
  • Sanofi
  • Galderma
  • Leo Pharma
  • Roviant Sciences
  • Otsuka Pharmaceuticals
Polaris Market Research
Global Dermatology Drugs Market Size & Share - Industry Report, 2022